Condition: Invasive Mammary Carcinoma · Metastatic Breast Cancer · Sponsor: Sonya Reid
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
This description comes directly from the study's public registry record.
Vanderbilt-Ingram Services for Timely Access · 800-811-8480 · cip@vumc.org
Always discuss trial participation with your own doctor first.
| University of Alabama Birmingham | Birmingham, Alabama, United States | Recruiting |
| Vanderbilt University/Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05693766